CClinicalTrials.gg
Not yet recruitingNCT06990646VR-ACTUpdated May 25, 2025

VR-ACT After Stroke: a Feasibility Study

An interventional study of VR-ACT and Sham-VR in Chronic Pain and Stroke, sponsored by University of Coimbra. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by University of Coimbra · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This exploratory project aims to develop and pilot test, in a parallel group randomized controlled trial (RCT) design, the feasibility, acceptability, and preliminary efficacy of a self-management virtual reality (VR) 8-week program for pain management and mental health in patients with chronic post-stroke pain (CPSP), in two assessment moments (pre- to post-intervention).

Read the detailed description

This project has three objectives: O1) to develop and test the feasibility and acceptability of a 8-week VR ACT program (VR-ACT) in a sample of CPSP patients; O2) to pilot test the efficacy of VR-ACT in improving pain, mental health, and adaptive psychological processes and skills, and in reducing the functional connectivity of the Triple Network (DMN, SN, and FPN); O3) To examine the cost-effectiveness of the VR-ACT. The current project will conduct a parallel group design Randomized Controlled Trial (RCT) and will follow a multi-method approach (qualitative and quantitative assessment).

02

Conditions studied

  • Chronic Pain
  • Stroke

Keywords

  • chronic post-stroke pain
  • contextual-behavioral approaches
  • virtual reality
  • acceptance and commitment therapy
03

In context

Stroke

7,283 studies on the registry are indexed under Stroke; 2,013 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 5,366 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Coimbra is the lead sponsor of 84 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • medical diagnosis of CPSP;
  • age between 18 and 80;
  • implicit de facto internet and computer literacy;
  • willingness to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • currently with active malignancy; -
  • severe cognitive impairment;
  • currently undergoing any psychological intervention or VR-delivered pain management program;
  • current severe psychiatric symptoms (i.e., psychosis; severe depression; non-suicidal self-injury; suicide attempt in the last month);
  • language impairment with severe comprehension deficit;
  • history of photosensitive epilepsy or previous experience of severe simulator sickness;
  • other neurological conditions (e.g., dementia; Parkinson´s).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    VR-ACT

    8 modules of 3D immersive skills training (2 targeting awareness regulation skills; 3 promoting acceptance; 3 focused on behavioral change and commitment to valued action)

    Behavioral: VR-ACT

  • Sham comparator
    Sham-VR

    8 2D non-immersive distracting video animations delivered through a VR headset

    Behavioral: Sham-VR

Interventions

  • BehavioralVR-ACT

    8 MODULES OF 3D VIRTUAL REALITY Modules 1 \& 2: Awareness Regulation Skills Modules 3, 4 \& 5: Acceptance of Pain and Internal Experiences Modules 6, 7 \& 8: Behavior Change and Valued Action

  • BehavioralSham-VR

    8 2D non-immersive distracting video-animations delivered through a VR headset.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    - The Numeric Rating Scale (NRS)

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Pain Impact

    - Pain Disability Index (PDI)

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Mental Health

    Mental Health: - Depression Anxiety and Stress Scale (DASS-21)

    Time frame: From enrollment to the end of treatment at 8 weeks

  4. Psychological and Physical Quality of Life

    - World Health Organization Quality of Life - Bref (WHOQOL- Bref)

    Time frame: From enrollment to the end of treatment at 8 weeks

Secondary outcomes

  1. Mindful Awareness

    Mindful Awareness: - Mindful Attention Awareness Scale (MAAS)

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Emotional Regulation

    Emotional Regulation: - Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Psychological Flexibility

    Psychological Flexibility: - Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT)

    Time frame: From enrollment to the end of treatment at 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06990646
Lead sponsor
University of Coimbra
Collaborators
Centro Hospitalar e Universitário de Coimbra, E.P.E.
Responsible party
Sérgio Andrade Carvalho (Doctor, University of Coimbra) — Principal investigator
First posted
May 25, 2025
Start date
Nov 2025 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
May 25, 2025

Study contacts

Sérgio A Carvalho, PhD
Contact
sergiocarvalho@fpce.uc.pt
+351 239 851 450

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion